AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 30865632 — intervention group
Group type: COMPARATOR
Intervention: Control villages (CCM alone)
Number of subjects: 4546
Study 30865632 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 4546
Study 27779768 — intervention group
Group type: EXPERIMENTAL
Intervention: Family-based education programme
Number of subjects: 100
Study 27779768 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 100
Study 27555618 — intervention group
Group type: EXPERIMENTAL
Intervention: Retrograde rhinopharyngeal clearance with physiological solution (0.9%) instillation
Number of subjects: 100
Study 27555618 — intervention group
Group type: COMPARATOR
Intervention: Nasopharyngeal aspiration
Number of subjects: 100
Study 27555618 — intervention group
Group type: EXPERIMENTAL
Intervention: Retrograde rhinopharyngeal clearance
Number of subjects: 100
Study 24651230 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% lidocaine
Number of subjects: 12
Study 24651230 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25% bupivacaine
Number of subjects: 12
Study 24651230 — intervention group
Group type: COMPARATOR
Intervention: Control (none specified)
Number of subjects: 12
Study 22099529 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychosocial intervention at follow-up
Number of subjects: 0
Study 22099529 — intervention group
Group type: COMPARATOR
Intervention: Baseline assessments (prognosis and depression)
Number of subjects: 0
Study 22099529 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of life at follow-up
Number of subjects: 0
Study 22099529 — intervention group
Group type: EXPERIMENTAL
Intervention: Depression at follow-up
Number of subjects: 0
Study 22099529 — intervention group
Group type: EXPERIMENTAL
Intervention: Social relationships needs
Number of subjects: 0
Study 19103995 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 10 mg/d
Number of subjects: 891
Study 19103995 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 891
Study 18422199 — intervention group
Group type: EXPERIMENTAL
Intervention: JWYY granules
Number of subjects: 76
Study 18422199 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine
Number of subjects: 76
Study 18422199 — intervention group
Group type: COMPARATOR
Intervention: Normal group
Number of subjects: 76
Study 15766343 — intervention group
Group type: EXPERIMENTAL
Intervention: KCI TheraPulse
Number of subjects: 62
Study 15766343 — intervention group
Group type: EXPERIMENTAL
Intervention: Hill-Rom Duo mattress
Number of subjects: 62
Study 15766343 — intervention group
Group type: COMPARATOR
Intervention: Both devices
Number of subjects: 62
Study 14570295 — intervention group
Group type: EXPERIMENTAL
Intervention: Most expensive cancer screening test
Number of subjects: 781
Study 14570295 — intervention group
Group type: COMPARATOR
Intervention: Less expensive cancer screening test
Number of subjects: 781
Study 14570295 — intervention group
Group type: EXPERIMENTAL
Intervention: Most expensive test justification
Number of subjects: 781
Study 14570295 — intervention group
Group type: COMPARATOR
Intervention: Less expensive test justification
Number of subjects: 781
Study 10827379 — intervention group
Group type: EXPERIMENTAL
Intervention: colestipol‐niacin
Number of subjects: 156
Study 10827379 — intervention group
Group type: EXPERIMENTAL
Intervention: QCA measures of lesion progression
Number of subjects: 156
Study 10827379 — intervention group
Group type: EXPERIMENTAL
Intervention: QCA measures of progression of coronary artery disease
Number of subjects: 156
Study 8912037 — intervention group
Group type: EXPERIMENTAL
Intervention: Bulimic women with a past history of anorexia nervosa
Number of subjects: 114
Study 8912037 — intervention group
Group type: COMPARATOR
Intervention: Bulimic women without a past history of anorexia nervosa
Number of subjects: 114
Study 1354088 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified basketball shoe
Number of subjects: 390
Study 1354088 — intervention group
Group type: COMPARATOR
Intervention: Standard infantry boots
Number of subjects: 390
Study 6502317 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenfluramine 1.5 mg/kg daily (0.75 mg/kg twice daily) for 8 months
Number of subjects: 14
Study 6502317 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 2 months
Number of subjects: 14
Study 31175425 — intervention group
Group type: EXPERIMENTAL
Intervention: Social counseling and therapy led by a social worker, six sessions of 60 min each in 3 weeks
Number of subjects: 354
Study 31175425 — intervention group
Group type: COMPARATOR
Intervention: Usual care: individual counseling meeting by request
Number of subjects: 354
Study 31175425 — intervention group
Group type: EXPERIMENTAL
Intervention: Social counseling and therapy led by a social worker
Number of subjects: 354
Study 30540808 — intervention group
Group type: EXPERIMENTAL
Intervention: ChAd63 MVA ME-TRAP
Number of subjects: 700
Study 25996804 — intervention group
Group type: EXPERIMENTAL
Intervention: Elastin hydrolysate
Number of subjects: 0
Study 25996804 — intervention group
Group type: EXPERIMENTAL
Intervention: Pro‐Gly
Number of subjects: 0
Study 24085341 — intervention group
Group type: COMPARATOR
Intervention: Beetroot juice containing 4.2 mmol NO(3‐) (SINGLE)
Number of subjects: 10
Study 24085341 — intervention group
Group type: COMPARATOR
Intervention: Beetroot juice containing 8.4 mmol NO(3‐) (DOUBLE)
Number of subjects: 10
Study 24085341 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0 mmol NO(3‐))
Number of subjects: 10
Study 23066769 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetyl cysteine (NAC) 2000 mg daily
Number of subjects: 0
Study 23066769 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 20509857 — intervention group
Group type: EXPERIMENTAL
Intervention: PIO (pioglitazone) 15 mg, twice a day
Number of subjects: 23
Study 20509857 — intervention group
Group type: COMPARATOR
Intervention: GLIM (glimepiride) 1 mg, twice a day
Number of subjects: 23
Study 18633055 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2% ropivacaine (basal 8 mL/h, bolus 4 mL)
Number of subjects: 50
Study 18633055 — intervention group
Group type: COMPARATOR
Intervention: 0.4% ropivacaine (basal 4 mL/h, bolus 2 mL)
Number of subjects: 50
Study 18633055 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2% ropivacaine
Number of subjects: 50
Study 18633055 — intervention group
Group type: COMPARATOR
Intervention: 0.4% ropivacaine
Number of subjects: 50
Study 15758880 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally-diluted BCP supplemented with potassium-chloride and magnesium-sulfate (Group M)
Number of subjects: 70
Study 15758880 — intervention group
Group type: COMPARATOR
Intervention: Standard 4:1-diluted blood-crystalloid BCP (Group C)
Number of subjects: 70
Study 11884967 — intervention group
Group type: EXPERIMENTAL
Intervention: biv‐WC (killed oral cholera vaccine)
Number of subjects: 247
Study 11884967 — intervention group
Group type: EXPERIMENTAL
Intervention: rBS‐WC (commercially available monovalent oral cholera vaccine)
Number of subjects: 247
Study 9928759 — intervention group
Group type: EXPERIMENTAL
Intervention: Mesocaval interposition shunt (MIS)
Number of subjects: 45
Study 9928759 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated sclerotherapy (ST)
Number of subjects: 45
Study 9928759 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 45
Study 7555507 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E (1,600 IU/day)
Number of subjects: 21
Study 7555507 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 1695491 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasmodium vivax sporozoite vaccine at 10 micrograms
Number of subjects: 13
Study 1695491 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasmodium vivax sporozoite vaccine at 100 micrograms
Number of subjects: 13
Study 1695491 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasmodium vivax sporozoite vaccine at 1,000 micrograms
Number of subjects: 13
Study 1695491 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasmodium vivax sporozoite vaccine (all doses)
Number of subjects: 13
Study 6968608 — intervention group
Group type: EXPERIMENTAL
Intervention: Haemorrhoidectomy
Number of subjects: 100
Study 6968608 — intervention group
Group type: COMPARATOR
Intervention: Rubber band ligation
Number of subjects: 100
Study 29336859 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy counselling by pharmacists based on the 'Managing Patients on Chemotherapy' module
Number of subjects: 2120
Study 29336859 — intervention group
Group type: COMPARATOR
Intervention: Control group (no counselling)
Number of subjects: 2120
Study 28510680 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral iron polysaccharide, 150 mg twice daily for 16 weeks
Number of subjects: 225
Study 28510680 — intervention group
Group type: COMPARATOR
Intervention: Placebo, 150 mg twice daily for 16 weeks
Number of subjects: 225
Study 28510680 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral iron polysaccharide
Number of subjects: 225
Study 28510680 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 225
Study 26152766 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucagon at euglycemia
Number of subjects: 29
Study 26152766 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucagon at hypoglycemia
Number of subjects: 29
Study 26152766 — intervention group
Group type: COMPARATOR
Intervention: Hypoglycemia group
Number of subjects: 29
Study 26152766 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucagon doses studied in both groups
Number of subjects: 29
Study 21923567 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical fusidic acid cream
Number of subjects: 151
Study 21923567 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose clarithromycin
Number of subjects: 151
Study 21923567 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin
Number of subjects: 151
Study 21923567 — intervention group
Group type: COMPARATOR
Intervention: Placebo cream
Number of subjects: 151
Study 21923567 — intervention group
Group type: COMPARATOR
Intervention: Placebo tablets
Number of subjects: 151
Study 20935558 — intervention group
Group type: EXPERIMENTAL
Intervention: Vacc-4x therapeutic immunization
Number of subjects: 27
Study 19102912 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute coronary syndrome (ACS)
Number of subjects: 210
Study 19102912 — intervention group
Group type: COMPARATOR
Intervention: Stable coronary artery disease (SCAD)
Number of subjects: 210
Study 19102912 — intervention group
Group type: EXPERIMENTAL
Intervention: High density lipoprotein‐cholesterol (HDL) levels > 1.04 mmol/L in ACS patients
Number of subjects: 210
Study 15980998 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical carbon fiber cage (n=20)
Number of subjects: 40
Study 15980998 — intervention group
Group type: COMPARATOR
Intervention: Allograft with plating (n=20)
Number of subjects: 40
Study 14568899 — intervention group
Group type: EXPERIMENTAL
Intervention: Velocity‐encoded CMR
Number of subjects: 24
Study 14568899 — intervention group
Group type: EXPERIMENTAL
Intervention: Velocity‐encoded CMR (repeated for 5 patients)
Number of subjects: 24
Study 14568899 — intervention group
Group type: COMPARATOR
Intervention: Doppler ultrasound
Number of subjects: 24
Study 10824623 — intervention group
Group type: EXPERIMENTAL
Intervention: St John's Wort extract (300 mg tablet standardized to 0.3% hypericin, taken three times a day for 14 days)
Number of subjects: 13
Study 8792755 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug therapy
Number of subjects: 593
Study 8792755 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 593
Study 1352083 — intervention group
Group type: EXPERIMENTAL
Intervention: roxatidine
Number of subjects: 0
Study 1352083 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 0
Study 6148842 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapist-directed prolonged exposure in vivo (PE)
Number of subjects: 103
Study 6148842 — intervention group
Group type: COMPARATOR
Intervention: Supportive therapy of dynamic type (ST)
Number of subjects: 103
Study 6148842 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxation therapy (R)
Number of subjects: 103
Study 6148842 — intervention group
Group type: COMPARATOR
Intervention: Basal therapy (B)
Number of subjects: 103
Study 31466618 — intervention group
Group type: EXPERIMENTAL
Intervention: Biomarker-guided therapy (NT-proBNP reduction to ≤1,000 pg/ml)
Number of subjects: 638
Study 31466618 — intervention group
Group type: COMPARATOR
Intervention: Usual care (GDMT alone)
Number of subjects: 638
Study 29783077 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged Exposure (PE)
Number of subjects: 162
Study 29783077 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual Reality Exposure (VRE)
Number of subjects: 162
Study 29783077 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 162
Study 27478305 — intervention group
Group type: EXPERIMENTAL
Intervention: Tr14 tablets
Number of subjects: 96
Study 27478305 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 96
Study 24481085 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoride varnish (FV)
Number of subjects: 200
Study 24481085 — intervention group
Group type: COMPARATOR
Intervention: Placebo varnish (PV)
Number of subjects: 200
Study 22510305 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide QW (once weekly)
Number of subjects: 686
Study 20119581 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple H. pylori eradication therapy for 7 days
Number of subjects: 0
Study 20119581 — intervention group
Group type: COMPARATOR
Intervention: No medication
Number of subjects: 0
Study 18705999 — intervention group
Group type: EXPERIMENTAL
Intervention: Ordinal method of Whitehead
Number of subjects: 54173
Study 18705999 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of means
Number of subjects: 54173
Study 18705999 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of medians method of Payne
Number of subjects: 54173
Study 18705999 — intervention group
Group type: EXPERIMENTAL
Intervention: Ordinal method for trials assessing thrombolysis
Number of subjects: 54173
Study 18705999 — intervention group
Group type: COMPARATOR
Intervention: Binary method of analysis
Number of subjects: 54173
Study 17072073 — intervention group
Group type: EXPERIMENTAL
Intervention: CMS patients
Number of subjects: 13
Study 14655915 — intervention group
Group type: EXPERIMENTAL
Intervention: Metyrapone (4.5 g)
Number of subjects: 8
Study 14655915 — intervention group
Group type: EXPERIMENTAL
Intervention: Metyrapone (6.0 g)
Number of subjects: 8
Study 14655915 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 11374615 — intervention group
Group type: EXPERIMENTAL
Intervention: Bispectral Index monitor
Number of subjects: 0
Study 11374615 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost of using Bispectral Index monitor
Number of subjects: 0
Study 9389945 — intervention group
Group type: EXPERIMENTAL
Intervention: Detailed information sheet
Number of subjects: 200
Study 9389945 — intervention group
Group type: COMPARATOR
Intervention: Minimal additional information
Number of subjects: 200
Study 7707151 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-measurement of blood pressure at home
Number of subjects: 44
Study 2885064 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoniazid (plus pyridoxine)
Number of subjects: 0
Study 2885064 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 29843226 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone (100 mg over 10 min)
Number of subjects: 30
Study 29843226 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline control)
Number of subjects: 30
Study 28404610 — intervention group
Group type: EXPERIMENTAL
Intervention: SARAH hand exercise programme
Number of subjects: 328
Study 28404610 — intervention group
Group type: COMPARATOR
Intervention: Best practice usual care group
Number of subjects: 328
Study 26687959 — intervention group
Group type: COMPARATOR
Intervention: Rituximab only
Number of subjects: 72
Study 26687959 — intervention group
Group type: EXPERIMENTAL
Intervention: Dulanermin and rituximab
Number of subjects: 72
Study 26687959 — intervention group
Group type: EXPERIMENTAL
Intervention: Dulanermin only
Number of subjects: 72
Study 26687959 — intervention group
Group type: EXPERIMENTAL
Intervention: Dulanermin (8 mg/kg)
Number of subjects: 72
Study 26687959 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab (375 mg/m2 weekly)
Number of subjects: 72
Study 26687959 — intervention group
Group type: EXPERIMENTAL
Intervention: Dulanermin with rituximab
Number of subjects: 72
Study 24191528 — intervention group
Group type: EXPERIMENTAL
Intervention: Adhesive tape (Group A)
Number of subjects: 120
Study 24191528 — intervention group
Group type: COMPARATOR
Intervention: Thomas tube holder (Group B)
Number of subjects: 120
Study 22075740 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 80
Study 20020079 — intervention group
Group type: EXPERIMENTAL
Intervention: Mouthwash containing Triclosan and Gantrez
Number of subjects: 30
Study 20020079 — intervention group
Group type: COMPARATOR
Intervention: Control group (unlabeled toothpaste without Triclosan and Gantrez)
Number of subjects: 30
Study 16957427 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril
Number of subjects: 42418
Study 16957427 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorthalidone
Number of subjects: 42418
Study 16957427 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxazosin
Number of subjects: 42418
Study 16957427 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 42418
Study 16957427 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall angioedema occurrence
Number of subjects: 42418
Study 16957427 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin-converting enzyme inhibitor arm
Number of subjects: 42418
Study 16957427 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall outcome
Number of subjects: 42418
Study 15004821 — intervention group
Group type: EXPERIMENTAL
Intervention: 595 nm pulsed dye laser treatment to one eye
Number of subjects: 26
Study 15004821 — intervention group
Group type: COMPARATOR
Intervention: Control eye (no treatment)
Number of subjects: 26
Study 11305631 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet S (stearic acid, 19g/day)
Number of subjects: 13
Study 11305631 — intervention group
Group type: COMPARATOR
Intervention: Diet P (palmitic acid)
Number of subjects: 13
Study 9033244 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg (0.25%) bupivacaine
Number of subjects: 97
Study 9033244 — intervention group
Group type: COMPARATOR
Intervention: 12.5 mg (0.125%) bupivacaine
Number of subjects: 97
Study 8511729 — intervention group
Group type: EXPERIMENTAL
Intervention: Bradykinin (1.9 mumol)
Number of subjects: 0
Study 8511729 — intervention group
Group type: EXPERIMENTAL
Intervention: Histamine (1.9 mumol)
Number of subjects: 0
Study 8511729 — intervention group
Group type: EXPERIMENTAL
Intervention: Bradykinin
Number of subjects: 0
Study 8511729 — intervention group
Group type: EXPERIMENTAL
Intervention: Histamine
Number of subjects: 0
Study 8511729 — intervention group
Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 0
Study 30265585 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical E6005
Number of subjects: 72
Study 29667099 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuing NSAIDs and DMARDs (group 1)
Number of subjects: 108
Study 29667099 — intervention group
Group type: EXPERIMENTAL
Intervention: Tapering NSAIDs and DMARDs by 50% (group 2)
Number of subjects: 108
Study 29667099 — intervention group
Group type: EXPERIMENTAL
Intervention: Discontinuing NSAIDs and DMARDs (group 3)
Number of subjects: 108
Study 29667099 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall (all groups)
Number of subjects: 108
Study 29667099 — intervention group
Group type: EXPERIMENTAL
Intervention: High ASDAS‐CRP at baseline
Number of subjects: 108
Study 29667099 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug discontinuation
Number of subjects: 108
Study 27343254 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored interactive multimedia computer program (IMCP)
Number of subjects: 0
Study 27343254 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailoring modules encouraging adherence to the tailored screening recommendation and discussion with the patient's PCP
Number of subjects: 0
Study 27343254 — intervention group
Group type: EXPERIMENTAL
Intervention: Better self-reported physical health and increased patient activation
Number of subjects: 0
Study 24793701 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent reinflation (IR)
Number of subjects: 36
Study 24793701 — intervention group
Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 36
Study 22642352 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative arousing sounds
Number of subjects: 0
Study 22642352 — intervention group
Group type: COMPARATOR
Intervention: Neutral sounds
Number of subjects: 0
Study 20346777 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.18% sodium hyaluronate ophthalmic solution (Rejena, Vismed)
Number of subjects: 444
Study 20346777 — intervention group
Group type: COMPARATOR
Intervention: Vehicle control
Number of subjects: 444
Study 16915361 — intervention group
Group type: EXPERIMENTAL
Intervention: Eye Movement Desensitisation and Reprocessing (EMDR)
Number of subjects: 48
Study 16915361 — intervention group
Group type: COMPARATOR
Intervention: Imaginal Exposure and Cognitive Restructuring (E+CR)
Number of subjects: 48
Study 16198883 — intervention group
Group type: EXPERIMENTAL
Intervention: Doppler tissue imaging (DTI) M-mode analysis of the anterior mitral leaflet
Number of subjects: 60
Study 11818177 — intervention group
Group type: EXPERIMENTAL
Intervention: Provider reminder with in-service training during INT1
Number of subjects: 534
Study 11818177 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospital-wide intervention (INT2)
Number of subjects: 534
Study 11818177 — intervention group
Group type: COMPARATOR
Intervention: Control group during INT1
Number of subjects: 534
Study 10368336 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 g glutamine in 330 ml glucose polymer solution
Number of subjects: 0
Study 10368336 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral glutamine alone
Number of subjects: 0
Study 10368336 — intervention group
Group type: EXPERIMENTAL
Intervention: Ingestion of glutamine and glucose polymer together
Number of subjects: 0
Study 10368336 — intervention group
Group type: COMPARATOR
Intervention: 8 g glutamine in 330 ml placebo
Number of subjects: 0
Study 8789313 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic hepatitis B and C patients
Number of subjects: 98